NCT02540655

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Steminent Biotherapeutics Inc. · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

Conditions

• Cerebellar Ataxia

Interventions

Type	Name	Description
BIOLOGICAL	Stemchymal®	Patients will receive Stemchymal® through intravenous infusion
PROCEDURE	Excipients	Patients will receive excipients through intravenous infusion

Timeline

• Start date: 2015-09-01
• Primary completion: 2021-02-26
• Completion: 2021-02-26
• First posted: 2015-09-04
• Last updated: 2022-10-27

Locations

1 site across 1 country: Taiwan